Below is an extract from the President/CEO Schlomo Yanai’s comments which relate to Mesoblast's Revascor product:"As I said earlier, our acquisition of Cephalon is enabling us to continue the process of establishing an important
branded pharmaceutical business with a robust pipeline... REVASCOR for the treatment of congestive heart failure,
scheduled to begin Phase 3 trials in Q2;... which is on track for filing this year assuming the successful outcome of their studies".
The above comments of the Teva CEO unambiguously state Teva's intentions with regard to Revascor. Vin
Below is an extract from the President/CEO Schlomo Yanai’s...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
97.0¢ |
Change
-0.005(0.51%) |
Mkt cap ! $1.107B | |||
| Open | High | Low | Value | Volume |
| 98.5¢ | 98.5¢ | 96.0¢ | $2.168M | 2.226M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 16000 | 96.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 97.0¢ | 86854 | 7 |
View Market Depth
| Last trade - 16.10pm 23/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |